Charles River Laboratories Announces Planned Management Changes

2/25/2015 11:03:42 AM

Charles River Laboratories International, Inc. (NYSE: CRL) today announced planned management changes which will be implemented over the course of 2015.

Chief Financial Officer Transition Plan

Thomas F. Ackerman, Corporate Executive Vice President and Chief Financial Officer, has announced that following a transition period, he will retire from Charles River Laboratories in February 2016. Mr. Ackerman joined Charles River in 1988, with over a decade of combined public accounting and international finance experience.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.